Related references
Note: Only part of the references are listed.A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061
Michelle A. Rudek et al.
CANCER (2014)
Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation
Yi Ling Teo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
Huixin Yu et al.
CLINICAL PHARMACOKINETICS (2014)
Review of therapeutic drug monitoring of anticancer drugs part two - Targeted therapies
Nicolas Widmer et al.
EUROPEAN JOURNAL OF CANCER (2014)
Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions
V. Kruse et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2014)
Sunitinib in combination with clarithromycin or azithromycin – is there a risk of interaction or not?
Edyta Szałek et al.
Pharmacological Reports (2014)
High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury
Ke Yu et al.
DRUG METABOLISM AND DISPOSITION (2014)
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma
Satoshi Noda et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study
Molouk Hadjibabaie et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors
Antoinette R. Tan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Evaluation of Utility of Pharmacokinetic Studies in Phase I Trials of Two Oncology Drugs
Kehua Wu et al.
CLINICAL CANCER RESEARCH (2013)
Gemfibrozil Impairs lmatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite
A. M. Filppula et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Are Drug Labels Static or Dynamic?
M. J. Seminerio et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
Maja J. A. de Jonge et al.
INVESTIGATIONAL NEW DRUGS (2013)
Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
Narayana I. Narasimhan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Preventing Adverse Drug-Drug Interactions: A Need for Improved Data and Logistics
Michael J. Seminerio et al.
MAYO CLINIC PROCEEDINGS (2013)
Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents
Steven J. Bowlin et al.
MAYO CLINIC PROCEEDINGS (2013)
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme
David M. Peereboom et al.
NEURO-ONCOLOGY (2013)
Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
Paul Martin et al.
Drugs in research & development (2013)
Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer
C. F. Xu et al.
ANNALS OF ONCOLOGY (2012)
Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
Yi Ling Teo et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
E. Brain et al.
BRITISH JOURNAL OF CANCER (2012)
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine
Jeffrey R. Infante et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations
Bella Pajares et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
Prevalence of the Coprescription of Clinically Important Interacting Drug Combinations Involving Oral Anticancer Agents in Singapore: A Retrospective Database Study
Yu Ko et al.
CLINICAL THERAPEUTICS (2012)
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
Yazdi K. Pithavala et al.
INVESTIGATIONAL NEW DRUGS (2012)
Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
Bo Gao et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Drug-Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug-Drug Interaction Prediction
Jane R. Kenny et al.
PHARMACEUTICAL RESEARCH (2012)
Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity
Stephen Castellino et al.
DRUG METABOLISM AND DISPOSITION (2012)
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study
Keith T. Flaherty et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors Focus on Pyrimidines, Pyridines and Pyrroles
Paola Di Gion et al.
CLINICAL PHARMACOKINETICS (2011)
Optimizing Chemotherapy: Concomitant Medication Lists
M. H. Hanigan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants
Chiaki Tanaka et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects
Richat Abbas et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Polypharmacy in elderly patients with cancer: clinical implications and management
Judith Lees et al.
LANCET ONCOLOGY (2011)
Phase 1 Pharmacokinetic and Drug-Interaction Study of Dasatinib in Patients With Advanced Solid Tumors
Faye M. Johnson et al.
CANCER (2010)
Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
Y. K. Pithavala et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Anticancer oral therapy: Emerging related issues
Giuseppe Luigi Banna et al.
CANCER TREATMENT REVIEWS (2010)
Metabolism considerations for kinase inhibitors in cancer treatment
Derek R. Duckett et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Drug interactions in metastatic breast cancer
Timothy Tyler
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects
Deborah A. Smith et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Gefitinib-phenytoin interaction is not correlated with the 14C-erythromycin breath test in healthy male volunteers
Stephanie Chhun et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Clinically Significant Drug-Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: A Delphi Survey of Oncology Pharmacists
Alexandre Chan et al.
CLINICAL THERAPEUTICS (2009)
The Simcyp® Population-based ADME Simulator
Masoud Jamei et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine
D. M. Ross
INTERNAL MEDICINE JOURNAL (2009)
Effect of gefitinib on warfarin antithrombotic activity
Susumu Arai et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia
Yanfeng Wang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Cytochrome P450s in the development of target-based anticancer drugs
Kedar Purnapatre et al.
CANCER LETTERS (2008)
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals
Craig Lammert et al.
HEPATOLOGY (2008)
Potential drug interactions in cancer patients receiving supportive care exclusively
Rachel P. Riechelmann et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2008)
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
S. E. Rosenbaum et al.
SUPPORTIVE CARE IN CANCER (2008)
Safety and anti-tumor activity of sorafenib (Nexavar((R))) in combination with other anti-cancer agents: a review of clinical trials
Chris H. Takimoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients
Stefan Pursche et al.
CURRENT CLINICAL PHARMACOLOGY (2008)
Potential drug interactions and duplicate prescriptions among cancer patients
Rachel P. Riechelmann et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Liver toxicity after treatment with gefitinib and anastrozole: Drug-drug interactions through cytochrome p450?
Paolo Carlini et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine
J. W. B. de Groot et al.
ANNALS OF ONCOLOGY (2006)
Drug interactions in cancer therapy
Charity D. Scripture et al.
NATURE REVIEWS CANCER (2006)
Cytochrome P450 and anticancer drugs
K Fujita
CURRENT DRUG METABOLISM (2006)
Drug-drug interactions in oncology: Why are they important and can they be minimized?
P Blower et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol
HC Swaisland et al.
CLINICAL PHARMACOKINETICS (2005)
Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia
E Gambillara et al.
DERMATOLOGY (2005)
Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
AE Bolton et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
C Dutreix et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia
SG O'Brien et al.
BRITISH JOURNAL OF CANCER (2003)
Drug interactions: Proteins, pumps, and P-450s
LE Shapiro et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2002)
Share Paper
